Luke Vale

Yes

RenuHEART: Cell therapy for the treatment of advanced heart failure. Funder: NIHR. Dates of Award: 01/12/2026 to 30/11/2031. Amount of award, Lead Health Economist. Maternity Disparities Consortium Research and Capacity Development Plans. Funder: NIHR. Dates of Award: 01/06/2026 to 31/04/2028. Amount of award, £4,362,871 Lead Health Economist STReptococcal Adaptive Platform (STRAP) trial. Funder: NIHR. Dates of Award: 01/01/2027 to 31/12/2032. Amount of award, £2,536,531 Lead Health Economist Geospatial targeting of comprehensive eyecare service enhancements in deprived London communities. Funder Vivensia. Dates of Award: 01/10/2026 to 30/09/2029. Amount of award, £ £1,303,303 Mentor A Randomised Controlled Trial of Durable Treatments for Neovascular Age-related Macular Degeneration. Funder: NIHR. Dates of Award: 01/01/2027 to 31/07/2030. Amount of award, Lead Health Economist Intelligent Navigation using AI to bust waiting times for urgent healthcare (INA). Funder: NIHR i4i. Dates of Award: 01/03/2026 to 30/09/2027. Amount of award £235,616, Lead Health Economist Cost Outcomes Study of Transcatheter aortic valve implantation with contemporary valves: COS-TAVI Trial. Funder: Industry funded. Date of award: : 01/06/2026 to: 31/03/2026. Amount of award £235,616, Principal Investigator NIHR-Climate Change and Health Security Health Protection Research Unit; Funder: NIHR. Date of award: : 01/04/2025 to: 31/03/2030. Amount of award £5,499,795. Lead Health Economist ESTAbLIsh – Endovascular strategy versus Surgical strategy for the Treatment for Acute Limb Ischaemia Assessing the clinical- and cost-effectiveness of endovascular strategy compared to surgical strategy for the treatment of acute limb ischaemia. Funder: NIHR HTA. Date of award: : 01/10/2025 to: 31/05/2029. Amount of award £2,247,611. Lead Health Economist Long-term outcomes of the Treatment of Advanced Glaucoma Study (TAGS): A multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma. Funder: NIHR HTA. Date of award: 01/10/2024 to 31/03/2027. Amount of award £465,054, Lead Health Economist Guidance on the economic evaluation of the health impacts of climate action. Funder: Wellcome Trust. Date of award: 01/09/2024 to 31/12/2025. Amount of award £384,411, Co-applicant. A randomised controlled trial to assess the clinical and cost-effectiveness of PSMA PET imaging to stage newly diagnosed high risk prostate cancer compared to standard care CT and bonescan imaging. Funder: PCUK. Date of award: 01/05/2025 to: 31/04/2032. Amount of award £1,950,188, Lead Health Economist Combination chemotherapy versus Bacillus Calmette-Guérin (BCG) for high-risk non-muscle invasive bladder cancer– a phase III multi-centre randomised controlled trial (COBRA). Funder: NIHR HTA. Date of award: 01/01/2025 to: 31/12/2031 (84 months). Amount of award £3,315,717, Lead Health Economist In2Air - The impact of ‘net-zero’ household energy interventions on indoor air quality, health and wellbeing. NIHR PHR. Date of award: 01/08/2024 to: 31/07/2027 (36 months). Amount of award £639,997, Lead Health Economist Non-surgical interventions for pelvic organ prolapse in women: a component network meta-analysis and cost-effectiveness analysis. Funder: NIHR HTA. Date of award: 01/12/2024 to: 31/01/2026 (14 months). Amount of award £426,914, Co-PI Accelerating Resilience and Climate Adaptation of Domestic Environments for vulnerable populations (ARCADE). Funder: NERC. Date of award: 01/01/2025 to: 31/01//2027. Amount of award £1,623,987, Lead Health Economist IntraVESical Preparations for Recurrent Urinary TrAct Infection Prevention (The VESPER Study): a multi-arm, multi-site open label randomised superiority trial. Funder: NIHR HTA. Date of award: 01/06/2024 to: 31/05/2028 (48 months). Amount of award £2,062,983, Lead Health Economist A randomised controlled trial of surgery versus no treatment to RESTORE cardiopulmonary function in severe pectus excavatum – The RESTORE Trial. Funder: NIHR HTA. Date of award: 01/01/2024 to: 30/04/2030 (76 months). Amount of award £1,969,505, Lead Health Economist Investigating the clinical and cost-effectiveness of CHildren’s Early Self-care Support in children with neurodisability: the CHESS cluster randomised controlled trial. Funder: NIHR HTA. Date of award: 01/02/2024 to: 31/01/2028. Amount of award £2,389,056, Lead Health Economist Co-design and mixed-methods evaluation of interventions to meet the unmet health needs of alcohol and substance using populations, with and without coexisting homelessness, in Sunderland. Funder: Sunderland City Council. Date of award: 01/07/2023 to 30/06/2025. Amount of the award £147,548, Lead Health Economist/Research Methodologist The FOLLOW UP study - a natural experiment comparing the clinical and cost-effectiveness of follow-up strategies after radical treatment for prostate cancer. Funder: NIHR HTA. Date of award: 01/07/2024 to: 30/06/2028. Amount of the award £1,836,294, Lead Health Economist A randomised controlled trial to assess screening for prostate cancer compared to current standard of care. Funder: PCUK. Date of award: 01/11/2023 to: 30/10/2042. Amount of the award £41,364,301, Lead Health Economist OPEN Trial Long-Term Follow-up. Funder: NIHR RfPB. Date of award: 01/11/2023 to: 30/09/2025. Amount of the award £151,000, Co-PI/Mentor Behavioural Sciences Policy Research Unit. Funder: NIHR. Date of award: 01/10/2023 to: 30/09/2028. Amount of the award £5,499,981, Lead Health Economist Evaluating the role of biparametric MRI and image-fusion targeted biopsies for detection of prostate cancer (Imperial Prostate 7 - Prostate Assessment using Comparative Interventions – Fast mri and Image-fusion for Cancer [IP7-PACIFIC]). Funder NIHR CRUK. Dates of award01/04/2022-31/03/2026. Amounts of award £1,176,927, co-applicant The cost and cost-effectiveness of Extracorporeal photopheresis in the treatment of Chronic Lung Allograft Dysfunction: An economic evaluation as part of the E-CLAD UK Trial. Funder MallanKot. Dates of award 01/06/2022-31/03/2027. Amounts of award £51,700, principal applicant A Real-World, In-Situ, Evaluation Of The Introduction And Scale-Up Of Robot-Assisted Surgical Services In The NHS: Evaluating Its Impact On Clinical And Service Delivery, Effectiveness And Cost (REINFORCE). Funder NIHR. Dates of award 01/01/2022-31/04/2025. Co-applicant The PARTIAL study – a randomised trial of the clinical and cost effectiveness of PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma. Funder NIHR HTA. Dates of award 01/03/2020-28/02/2030. Amounts of award £1,876,106.11, co-applicant Technology Assessment Reviews. Funder NIHR. Dates of award 01/04/2022-31/03/2027. Amounts of the award £2,900,000, principal applicant ATNEC - Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy. Funder NIHR HTA. Dates of award 01/01/2022-31/12/2025. Amounts of award £1,294,912.38, co-applicant OpticAl Coherence TomograpHy Angiography for the dEtection of Neovascular Age-related Macular Degeneration: a Comprehensive Diagnostic Accuracy Study - the ATHENA study. Funder NIHR HTA. Dates of award 01/11/2020-31/10/2027. Amounts of award £1,594,756.99, co-applicant Tele-opHthalmology-enablEd and ARtificial Intelligence-ready referral pathway for community optomEtry referralS of retinal disease: the HERMES study - a Cluster Randomised Superiority Trial with a linked Observational Diagnostic Accuracy Study. Funder NIHR HTA. Dates of award 01/11/2019-31/10/2025. Amounts of award £1,292,682, co-applicant RenuHEART: Cell therapy for the treatment of advanced heart failure. Funder: NIHR. Dates of Award: 01/12/2026 to 30/11/2031. Amount of award, Lead Health Economist. Maternity Disparities Consortium Research and Capacity Development Plans. Funder: NIHR. Dates of Award: 01/06/2026 to 31/04/2028. Amount of award, £4,362,871 Lead Health Economist STReptococcal Adaptive Platform (STRAP) trial. Funder: NIHR. Dates of Award: 01/01/2027 to 31/12/2032. Amount of award, £2,536,531 Lead Health Economist Geospatial targeting of comprehensive eyecare service enhancements in deprived London communities. Funder Vivensia. Dates of Award: 01/10/2026 to 30/09/2029. Amount of award, £ £1,303,303 Mentor A Randomised Controlled Trial of Durable Treatments for Neovascular Age-related Macular Degeneration. Funder: NIHR. Dates of Award: 01/01/2027 to 31/07/2030. Amount of award, Lead Health Economist Intelligent Navigation using AI to bust waiting times for urgent healthcare (INA). Funder: NIHR i4i. Dates of Award: 01/03/2026 to 30/09/2027. Amount of award £235,616, Lead Health Economist Cost Outcomes Study of Transcatheter aortic valve implantation with contemporary valves: COS-TAVI Trial. Funder: Industry funded. Date of award: : 01/06/2026 to: 31/03/2026. Amount of award £235,616, Principal Investigator NIHR-Climate Change and Health Security Health Protection Research Unit; Funder: NIHR. Date of award: : 01/04/2025 to: 31/03/2030. Amount of award £5,499,795. Lead Health Economist ESTAbLIsh – Endovascular strategy versus Surgical strategy for the Treatment for Acute Limb Ischaemia Assessing the clinical- and cost-effectiveness of endovascular strategy compared to surgical strategy for the treatment of acute limb ischaemia. Funder: NIHR HTA. Date of award: : 01/10/2025 to: 31/05/2029. Amount of award £2,247,611. Lead Health Economist Long-term outcomes of the Treatment of Advanced Glaucoma Study (TAGS): A multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma. Funder: NIHR HTA. Date of award: 01/10/2024 to 31/03/2027. Amount of award £465,054, Lead Health Economist Guidance on the economic evaluation of the health impacts of climate action. Funder: Wellcome Trust. Date of award: 01/09/2024 to 31/12/2025. Amount of award £384,411, Co-applicant. A randomised controlled trial to assess the clinical and cost-effectiveness of PSMA PET imaging to stage newly diagnosed high risk prostate cancer compared to standard care CT and bonescan imaging. Funder: PCUK. Date of award: 01/05/2025 to: 31/04/2032. Amount of award £1,950,188, Lead Health Economist Combination chemotherapy versus Bacillus Calmette-Guérin (BCG) for high-risk non-muscle invasive bladder cancer– a phase III multi-centre randomised controlled trial (COBRA). Funder: NIHR HTA. Date of award: 01/01/2025 to: 31/12/2031 (84 months). Amount of award £3,315,717, Lead Health Economist In2Air - The impact of ‘net-zero’ household energy interventions on indoor air quality, health and wellbeing. NIHR PHR. Date of award: 01/08/2024 to: 31/07/2027 (36 months). Amount of award £639,997, Lead Health Economist Non-surgical interventions for pelvic organ prolapse in women: a component network meta-analysis and cost-effectiveness analysis. Funder: NIHR HTA. Date of award: 01/12/2024 to: 31/01/2026 (14 months). Amount of award £426,914, Co-PI Accelerating Resilience and Climate Adaptation of Domestic Environments for vulnerable populations (ARCADE). Funder: NERC. Date of award: 01/01/2025 to: 31/01//2027. Amount of award £1,623,987, Lead Health Economist IntraVESical Preparations for Recurrent Urinary TrAct Infection Prevention (The VESPER Study): a multi-arm, multi-site open label randomised superiority trial. Funder: NIHR HTA. Date of award: 01/06/2024 to: 31/05/2028 (48 months). Amount of award £2,062,983, Lead Health Economist A randomised controlled trial of surgery versus no treatment to RESTORE cardiopulmonary function in severe pectus excavatum – The RESTORE Trial. Funder: NIHR HTA. Date of award: 01/01/2024 to: 30/04/2030 (76 months). Amount of award £1,969,505, Lead Health Economist Investigating the clinical and cost-effectiveness of CHildren’s Early Self-care Support in children with neurodisability: the CHESS cluster randomised controlled trial. Funder: NIHR HTA. Date of award: 01/02/2024 to: 31/01/2028. Amount of award £2,389,056, Lead Health Economist Co-design and mixed-methods evaluation of interventions to meet the unmet health needs of alcohol and substance using populations, with and without coexisting homelessness, in Sunderland. Funder: Sunderland City Council. Date of award: 01/07/2023 to 30/06/2025. Amount of the award £147,548, Lead Health Economist/Research Methodologist The FOLLOW UP study - a natural experiment comparing the clinical and cost-effectiveness of follow-up strategies after radical treatment for prostate cancer. Funder: NIHR HTA. Date of award: 01/07/2024 to: 30/06/2028. Amount of the award £1,836,294, Lead Health Economist A randomised controlled trial to assess screening for prostate cancer compared to current standard of care. Funder: PCUK. Date of award: 01/11/2023 to: 30/10/2042. Amount of the award £41,364,301, Lead Health Economist OPEN Trial Long-Term Follow-up. Funder: NIHR RfPB. Date of award: 01/11/2023 to: 30/09/2025. Amount of the award £151,000, Co-PI/Mentor Behavioural Sciences Policy Research Unit. Funder: NIHR. Date of award: 01/10/2023 to: 30/09/2028. Amount of the award £5,499,981, Lead Health Economist Evaluating the role of biparametric MRI and image-fusion targeted biopsies for detection of prostate cancer (Imperial Prostate 7 - Prostate Assessment using Comparative Interventions – Fast mri and Image-fusion for Cancer [IP7-PACIFIC]). Funder NIHR CRUK. Dates of award01/04/2022-31/03/2026. Amounts of award £1,176,927, co-applicant The cost and cost-effectiveness of Extracorporeal photopheresis in the treatment of Chronic Lung Allograft Dysfunction: An economic evaluation as part of the E-CLAD UK Trial. Funder MallanKot. Dates of award 01/06/2022-31/03/2027. Amounts of award £51,700, principal applicant A Real-World, In-Situ, Evaluation Of The Introduction And Scale-Up Of Robot-Assisted Surgical Services In The NHS: Evaluating Its Impact On Clinical And Service Delivery, Effectiveness And Cost (REINFORCE). Funder NIHR. Dates of award 01/01/2022-31/04/2025. Co-applicant The PARTIAL study – a randomised trial of the clinical and cost effectiveness of PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma. Funder NIHR HTA. Dates of award 01/03/2020-28/02/2030. Amounts of award £1,876,106.11, co-applicant Technology Assessment Reviews. Funder NIHR. Dates of award 01/04/2022-31/03/2027. Amounts of the award £2,900,000, principal applicant ATNEC - Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy. Funder NIHR HTA. Dates of award 01/01/2022-31/12/2025. Amounts of award £1,294,912.38, co-applicant OpticAl Coherence TomograpHy Angiography for the dEtection of Neovascular Age-related Macular Degeneration: a Comprehensive Diagnostic Accuracy Study - the ATHENA study. Funder NIHR HTA. Dates of award 01/11/2020-31/10/2027. Amounts of award £1,594,756.99, co-applicant Tele-opHthalmology-enablEd and ARtificial Intelligence-ready referral pathway for community optomEtry referralS of retinal disease: the HERMES study - a Cluster Randomised Superiority Trial with a linked Observational Diagnostic Accuracy Study. Funder NIHR HTA. Dates of award 01/11/2019-31/10/2025. Amounts of award £1,292,682, co-applicant

No

Yes

Sign-off editor - present CCEMG method group convenor until 2020 Editor EPOC until 2020 Editor/co-ordinating Editor Cochrane Incontinence until 2021

Yes

Spouse was CEO of AMLO Diagnostics until Sept 2025 and is currently CEO of inoviv from Feb 2026